Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico

Ruíz-Palacios, Guillermo M.; Beigel, John H.; Guerrero, M. Lourdes; Bellier, L.; Tamayo, Ramiro; Cervantes, Patricia Parra; Álvarez, Francisco Blanco; Aguilar-Ituarte, Felipe; López, Juan Guillermo

doi:10.1080/21645515.2019.1678997

Cited by 6 publications

(5 citation statements)

References 23 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study has generated results that provide clear information and elements of consideration for switching from one vaccine to another within the immunization program (public health and budget impacts); using a validated approach with a model structure published in the literature. 9 , 10 , 12 Another strength of this model is its adjustments to local characteristics. The model was mainly informed with high-quality local data.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay

Arbo¹,

Martinez-Cellular²,

Vázquez

et al. 2022

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

This study aimed to investigate the public health and economic benefit of using a quadrivalent influenza vaccine (QIV) instead of a trivalent influenza vaccine (TIV) in past seasons in Paraguay. The budget impact of switching from TIV to QIV in the Immunization Program was also evaluated. The adapted model includes two modules. The first compared retrospectively Health and Economic outcomes resulting from the use of QIV instead of TIV. The second forecast the spending and savings that would be associated with the switch from TIV to QIV. Our findings estimate that the switch from TIV to QIV during the seasons 2012 to 2017 could have prevented around 2,600 influenza cases, 67 hospitalizations and 10 deaths. An alternative scenario using standardized estimates of the burden of influenza showed that 234 influenza-related hospitalizations and 29 deaths could have been prevented. The estimated annual budget impact of a full switch from TIV to QIV was around USD1,6 million both from the payer and societal perspectives. Those results are mainly driven by vaccine prices and coverage rate. In sum, this manuscript describes how the use of QIV instead of TIV could have prevented influenza cases and subsequent complications that led to hospitalizations and deaths. This could have generated savings for the health system and society, offsetting part of the additional investment needed to switch from TIV to QIV.

show abstract

Section: Discussionmentioning

confidence: 99%

“…30 The same approach has already been reported in the literature. 10–12 To these attack rates, we applied probabilities of consultations, hospitalizations and deaths per case from the literature. 23 The alternative rates are presented in Supplementary Table S2.…”

Section: Methodsmentioning

confidence: 99%

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay

Arbo¹,

Martinez-Cellular²,

Vázquez

et al. 2022

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies from all regions of the world have demonstrated the significant economic benefits of QIV use compared with TIV [ 9 , 10 , 11 , 16 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ]. Currently in Argentina, the National Immunization Program recommends annual receipt of TIV for individuals classified as “at risk”.…”

Section: Discussionmentioning

confidence: 99%

“…Another limitation is that real incidence rates for a non-vaccinated population are simply unobtainable in Argentina, because almost a decade has passed since the start of the influenza vaccination program. This obstacle was overcome by other researchers by the inclusion of the incidence of randomized clinical trials where vaccine efficacy was originally tested in their models [ 10 , 55 , 56 , 57 ]. However, these trials have been conducted in other countries, many of them in the northern hemisphere, where climate issues and population behavior may affect influenza attack rates in a very different way, and hence may not be representative of local epidemiology.…”

Section: Discussionmentioning

confidence: 99%

“…Jamotte et al estimate that the use of QIV in Brazil, Colombia, and Panama would significantly reduce the burden of seasonal influenza disease in these countries [ 8 ]. Studies from Mexico and Brazil have shown that the use of quadrivalent rather than trivalent vaccines in these countries would be cost-effective [ 9 , 10 , 11 ]. These and other data suggest that the introduction of QIV in Argentina could potentially be of benefit.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina

Urueña

Micone

Magneres³

et al. 2021

Vaccines

View full text Add to dashboard Cite

The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014–2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost–effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer’s and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in ≥ 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults.

show abstract

Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review

Warmath¹,

Ortega-Sánchez²,

Duca³

et al. 2023

Value in Health

View full text Add to dashboard Cite

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico

Cited by 6 publications

References 23 publications

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina

Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review

Contact Info

Product

Resources

About